Citigroup Inc. upgraded shares of Indivior PLC (LON:INDV) to a buy rating in a research report released on Wednesday morning. Citigroup Inc. currently has GBX 490 ($6.44) target price on the specialty pharmaceutical company’s stock, up from their previous target price of GBX 280 ($3.68).

A number of other analysts have also recently issued reports on the company. Numis Securities Ltd reissued a buy rating and set a GBX 500 ($6.58) price objective on shares of Indivior PLC in a research report on Monday, October 30th. Stifel Nicolaus reaffirmed a buy rating and issued a GBX 400 ($5.26) price target on shares of Indivior PLC in a research report on Friday, September 15th. Jefferies Group LLC reduced their price target on Indivior PLC from GBX 540 ($7.10) to GBX 358 ($4.71) and set a buy rating for the company in a research report on Friday, September 8th. Finally, Royal Bank Of Canada reaffirmed an outperform rating and issued a GBX 470 ($6.18) price target on shares of Indivior PLC in a research report on Thursday, August 3rd. One analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus price target of GBX 448.14 ($5.89).

Indivior PLC (INDV) traded down GBX 1.80 ($0.02) on Wednesday, reaching GBX 383.10 ($5.04). The company had a trading volume of 2,438,976 shares, compared to its average volume of 2,690,000. Indivior PLC has a 52-week low of GBX 246.50 ($3.24) and a 52-week high of GBX 421.50 ($5.54).

ILLEGAL ACTIVITY WARNING: “Indivior PLC (INDV) Upgraded to Buy at Citigroup Inc.” was first reported by Daily Political and is owned by of Daily Political. If you are accessing this report on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/11/09/indivior-plc-indv-upgraded-to-buy-at-citigroup-inc.html.

About Indivior PLC

Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue and central nervous system (CNS) disorders/schizophrenia.

Analyst Recommendations for Indivior PLC (LON:INDV)

Receive News & Ratings for Indivior PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior PLC and related companies with MarketBeat.com's FREE daily email newsletter.